Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals announced positive results from a phase 3 study of Repretinib in gastrointestinal stromal tumors.
Doctors at NYU Langone Hospital—Brooklyn Help Patient with Rare Stomach Cancer Turn His Life Around
NYU gastroenterologists are using advanced imagery and robotic surgery techniques to improve the detection and removal of stomach tumors.
Optimal Duration of First-Line Chemotherapy for Advanced Gastric Cancer: Data from the AGAMENON Registry
A study concludes that longer first-line chemotherapy regimens for patients with gastric cancer has a protective effect, and that discontinuing platinum chemo... Read More
The diagnostic value of serum gastrokine 1 (GKN1) protein in gastric cancer
A new study finds that levels of the protein gastrokine 1 (GKN1) in the blood can serve as a biomarker for identifying... Read More
Gastric cancer risks due to CDH1 variant likely overestimated
A new study suggests that people with CDH1 mutations might not be at as high a risk for gastric cancer as previously... Read More
In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1
A study by GeneDx shows that the lifetime risk for gastric cancer in people with pathogenic CDH1 variants is 42% for men... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed longer survival... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate in patients... Read More
GCF-AGA Grant Recipient El-Zaatari Charts Progress on Three Research Efforts
Ever since Mohamad El-Zaatari, Ph.D., research assistant professor at the University of Michigan, received the first GCF-American Gastroenterology Association grant in 2014,... Read More
